Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

NCT03674294 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

248

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Neoplasms
Chemotherapy-induced Nausea and Vomiting

Interventions

DRUG: Aprepitant
DRUG: Palonosetron
DRUG: Dexamethasone
DRUG: Placebo Oral Tablet

Sponsor

Sun Yat-sen University